page_desktop_bannerpage_mobile_banner

ATTR-CM IS A MULTISYSTEM,
PROGRESSIVE, FATAL DISEASE1–4

ATTR-CM IS AN UNDERDIAGNOSED, RAPIDLY PROGRESSIVE, DEBILITATING AND FATAL DISEASE1

1

In ATTR-CM, TTR protein misfolds and becomes toxic5,6

2

Toxic misfolded TTR* accumulates as amyloid fibrils, which infiltrate the heart and other tissues1,5

3

Relentless production and deposition of toxic misfolded TTR fibrils results in progressive tissue damage and organ dysfunction and, ultimately, death1,5

4

Toxic misfolded TTR deposits can accumulate in the extracellular space of the myocardium, causing hypertrophy and stiffness, which can result in a restrictive physiology and diastolic dysfunction5,7

5

These changes can manifest clinically as heart failure5,7

Infiltrated Myocardium

*Toxic TTR refers to the misfolded TTR proteins in patients with ATTR-CM which aggregate into amyloid fibrils, causing multisystemic deposits.5,6

Infiltrated Myocardium
centercontent-bg-desktop_0_3centercontent-bg-mobile

Life expectancy for patients with ATTR-CM is

2–6
YEARS

from the point of diagnosis1

ANY DELAY IN DIAGNOSIS OF ATTR-CM CAN RESULT IN PROGRESSIVE DISABILITY AND WORSE OUTCOMES2,4,8

Diagnosis is often delayed by as much as 6 years from symptom onset due to lack of awareness, even with hallmark signs and symptoms and clear diagnostic guidelines2,4

  • Diagnostic delay can result in late initiation of specific treatments for ATTR-CM2,4,8
  • Early initiation of these treatments is vital for patients to derive the greatest benefit from them and stop or delay further progression of disease2,4,8
ATTR-CM is rapidly progressive, ACT FAST. Learn how to recognize the red flag symptoms
Pattern of Progression in ATTR CM
FIND OUT WHERE YOU CAN REFER YOUR PATIENTS